Duvelisib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 209 publications

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

Journal: Blood advances
Published: January 29, 2026

Estimation of the metabolic stability of omipalisib in human liver microsomes employing an ultra-fast UPLC-MS/MS approach: in silico screening for structural alarms and metabolic lability.

Estimation of the metabolic stability of omipalisib in human liver microsomes employing an ultra-fast UPLC-MS/MS approach: in silico screening for structural alarms and metabolic lability.

Journal: Analytical methods : advancing methods and applications
Published: January 26, 2026

Cutaneous and Systemic Complications in Primary CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma.

Cutaneous and Systemic Complications in Primary CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma.

Journal: Cureus
Published: December 26, 2025

Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.

Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.

Journal: American journal of clinical dermatology
Published: December 01, 2025

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

Journal: Biochemical and biophysical research communications
Published: December 01, 2025

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation.

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation.

Journal: Blood advances
Published: November 04, 2025

Duvelisib upregulates p27 expression and leads to intestinal damage via the NEDD4L/CK1ε axis.

Duvelisib upregulates p27 expression and leads to intestinal damage via the NEDD4L/CK1ε axis.

Journal: Biochemical pharmacology
Published: November 01, 2025

A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.

A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.

Journal: European journal of haematology
Published: August 22, 2025

Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics.

Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics.

Journal: Cureus
Published: August 18, 2025

Enantiomeric separation of duvelisib by Electrokinetic Chromatography. Application to the analysis of pharmaceutical formulations and determination in serum and wastewater samples previous μSPEed preconcentration.

Enantiomeric separation of duvelisib by Electrokinetic Chromatography. Application to the analysis of pharmaceutical formulations and determination in serum and wastewater samples previous μSPEed preconcentration.

Journal: Talanta
Published: August 15, 2025

Endpoint Exposure-Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials.

Endpoint Exposure-Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials.

Journal: Clinical pharmacology and therapeutics
Published: July 21, 2025

Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib.

Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib.

Journal: Clinical drug investigation
Published: June 24, 2025
Showing 1-12 of 209

Last Updated: 04/28/2026